Acrivon Therapeutics Inc.

NASDAQ: ACRV
Share price (3/25/25): $5.39
Market cap (3/25/25): $168 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 09/30/24 Q3

ended 06/30/24 Q2

ended 03/31/24 Q1

ended 12/31/23 FY 2023

ended 09/30/23 Q3

Prospectuses and Registrations Filter

Shelf registration

Registration of securities for employees

Shelf registration

Registration of securities for employees

Registration of securities for employees

Ownership Filter

Peterson Katharine

Holm-Jorgensen Rasmus

News Filter

Investor Presentation

Change in Directors, Officers or Compensation, Financial Statements or Exhibits

Reports Third Quarter 2024 Financial Results and Business Highlights

Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity

- Confirmed Overall Response Rate (ORR) = 62.5% (95% CI, 30.4-86.5) Observed in Prospectively-Selected ACR-368 OncoSignature-positive (BM+) Patients With Endometrial Cancer

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Other Filter

Notice of effectiveness

Scanned paper annual report submission

Correspondence with the SEC

Letter from the SEC

Notice of effectiveness